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Cellular events in the evolution of experimental diabetic nephropathy.
In several models of progressive glomerular disease, mesangial cell
proliferation, phenotypic change and increased growth factor expression
precede up-regulation of genes for extracellular matrix components
(ECM) and mesangial expansion. To examine these events in diabetic
nephropathy (DN) we conducted sequential studies of glomeruli in rats
with streptozotocin induced DN. We found prominent mesangial cell
proliferation at three days (4.34 2.24PCNA + cells/glom vs. 1.6 0.74
in controls, P < 0.001) associated with increased n-actin expression.
PDGF B-chain mRNA was slightly increased at day one, and PDGF
B-chain immunostaining was slightly increased at days one and six.
Staining for bFGF was significantly increased at three days (2.2 0.6 vs.
1.2 0.1 in controls, P < 0.01). There was also an early increase in
platelets in glomeruli of diabetic animals, and platelet depletion signifi-
cantly inhibited the early phase of proliferation. In addition to mesangial
cell proliferation, a prominent glomerular macrophage infiltration began
at day three and peaked at day 30 (3.94 1.47 vs. 2.08 1.13 in controls,
P < 0.01). TGF-J3 mRNA increased at days 14 and 30. Insulin treatment
prevented mesangial cell proliferation, actin expression, and macrophage
infiltration, and normalized TGF-13 expression at 14 and 30 days. These
multiple cellular events preceded any detectable increases in glomerular
gene expression or deposition of collagen I, IV or laminin.
The most common cause of end-stage renal disease in the
United States is diabetic nephropathy (DN), accounting for
almost a third of all new patients requiring dialysis [1]. The
pathogenesis of DN is incompletely understood but is generally
believed to involve a disorder of glomerular cell metabolism
leading to accumulation of both basement membrane and non-
basement membrane extracellular matrix (ECM) components,
resulting in expansion of the mesangial matrix and thickening of
glomerular basement membrane (GBM) [2]. Although hypergly-
cemia is the underlying metabolic abnormality, multiple other
mechanisms have also been proposed including abnormal glomer-
ular hemodynamic factors [3, 4], aberrant metabolic pathways [5,
6], glycosylation of glomerular structures [7], and abnormal
growth factor expression leading to ECM accumulation [8].
Recent studies from our laboratory have suggested that an early
phase of mesangial cell proliferation and alteration in phenotype
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may also be central to the development of later mesangial matrix
expansion and glomerular sclerosis in models of both immune and
non-immune glomerular injury [reviewed in 9, 10]. Thus, in the
Thy 1.1 model of immune-mediated mesangial proliferative gb-
merulonephritis, mesangial matrix expansion is preceded by a
phase of active mesangial cell proliferation, which is mediated by
complement and platelets, and involves increased expression or
release of growth factors including basic fibroblast growth factor
(bFGF), platelet-derived growth factor (PDGF) and its receptor,
and transforming growth factor beta (TGF-13) [11]. Other char-
acteristics of this activated mesangial cell phenotype include de
novo expression of a-smooth muscle actin and increased extracel-
lular matrix production accompanied by over production of matrix
modifying enzymes [10]. Mesangial cell proliferation also pre-
cedes matrix expansion in non-immune models of progressive
glomerular disease such as the remnant kidney model [12], and
gbomeruloscierosis in mice transgenic for growth hormone (GH)
[13, 14] and SV4O [15, 16]. We therefore hypothesized that
glomerular cell proliferation might precede, and perhaps predict,
the development of glomeruloscierosis in DN as well.
In this study we report that mesangial cell proliferation occurs
early in experimentally induced DN, is associated with a glomer-
ular platelet infiltrate and increased expression of growth factors
(bFGF, PDGF), and precedes detectable changes in mesangial
ECM deposition. A later phase of glomerular macrophage infil-
tration was associated with increased expression of TGF-13 that
may also be related to the development of chronic glomensloscle-
rosis in diabetic nephropathy. These newly recognized cellular
events in early diabetic nephropathy may provide important
insights into the pathogenesis of this condition.
Methods
Experimental design
Experimental diabetes was induced in 96 male, 120 to 140 g,
Sprague-Dawley rats (Simonsen Laboratories, Gilroy, CA, Bantin
and Kingman, Edmonds, WA, USA), with streptozotocin (Sigma,
St. Louis, MO, USA), 65 mg/kg, dissolved in sodium citrate buffer
(pH 4.5), given intravenously. Forty-two rats were treated with
daily injections of insulin (protamine zinc and ultralente, Eli Lilly
and Company, Indianapolis, IN, USA) in doses of 5 to 12 units
subcutaneously every 24 hours to maintain blood glucose less than
150 mg/dl. Fifty-four rats served as controls and were injected with
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equivalent doses of sodium citrate buffer. Animals were housed in
cages with standard rat chow and water ad libitum. Serum glucose
was measured at multiple time points by glucometer reading, and
daily in rats receiving insulin by serum chemstrip bG(R) (Boehr-
inger Mannheim Corp., Indianapolis, IN, USA) and/or with urine
glucose measurements using Tes-Tape (R) glucose enzymatic
strips (Eli Lilly). Serum glucose was measured in all animals at
sacrifice by a Paramax ZY 720 Analyzer (Baxter, McGaw Park,
IL, USA). Urine protein was measured at two and four weeks.
Renal tissue was obtained in separate groups of animals at one,
three, six, 14, and 30 days. Biopsies and glomerular mRNA were
obtained at the above selected time points to stain for cell
proliferation, growth factor expression and extracellular matrix
components, and to assess gene expression of growth factors and
matrix components.
Renal morphology
Renal biopsies were fixed in methyl Carnoy's solution and
embedded in paraffin. Four micrometer sections were stained with
periodic acid and Schiff's reagent (PAS), and counter stained with
hematoxylin. Biopsies were assessed for basement membrane
changes and sclerosis. Total glomerular cellularity was deter-
mined by counting the number of nuclei per glomerular cross-
section and subtracting the number of macrophage/monocytes
stained by ED-i antibody (see below). Extracellular matrix expan-
sion was assessed on 4 m sections of tissue using a modified
Gomori's silver methenamine stain, and specific extracellular
matrix antibodies.
Electron microscopy
Tissues were prepared and processed as previously described
[17]. Biopsies were studied at days one and three for ultrastruc-
tural changes and platelet infiltration.
Immunohistochemical staining
Tissue was sectioned (4 tm) and stained using an indirect immu-
noperoxidase or immuno-alkaline phosphatase method (PDGF B
chain) as previously described [12, 18, 19]. Antigens evaluated and
antibodies used included the following: Proliferating cell nuclear
antigen (PCNA) using 19A2 (American Biotech Inc., Plantation,
FL, USA) [20]; a-smooth muscle actin using a-SM-i (gift of G.
Gabbiani) [21]; macrophages, monocytes and dendritic cells using
the murine monoclonal antibody ED-i (Bioproducts for Science,
Indianapolis, IN, USA); platelets using the murine monoclonal
antibody PL-1 (gift of W.W. Baker, Groning, Netherlands) [22];
mesangial cells using the anti-thy 1.1 monoclonal antibody OX-7
(Serotec Ltd., Blackhorn Bicester, UK) [23]; common leukocyte
antigen expressed by B lymphocytes and some T lymphocytes
using OX-22 (Accurate Chemical Corporation, Westbury, NY,
USA); rat neutrophils using the RP-3 antibody (gift of F. Sendo,
Yamagata, Japan) [24]; bFGF using the monoclonal antibody
DE6, (gift of T. Reilly, DuPont-Merck, Wilmington, DE, USA)
[25]; PDGF B-chain using the monoclonal antibody PDGF-007
(Mochida Pharmaceutical, Tokyo, Japan) [26]; and PDGF 13-re-
ceptor using a rabbit polyclonal antibody to the 13-subunit of the
PDGF-receptor (gift of Ron Seifert, Seattle, WA, USA) [19].
Polyclonal antibodies to laminin (Chemicon, Temecula, CA,
USA); heparan sulfate proteoglycan (HSPG; gift of J.R. Couch-
man, Birmingham, AL, USA) [27]; collagen type I (gift of L.
Iruela-Arispe, Seattle, WA, USA) [28]; and collagen type IV
(Southern Biotech, Birmingham, AL, USA) were also utilized.
Controls included known positive and negative tissue as well as
staining with an irrelevant antibody of the same isotype. All
biopsies within a group were stained at the same time.
Each biopsy was reviewed and scored by an observer blinded to
which group the animal belonged. At least 20 consecutive cross-
sections of cortical glomeruli containing more than 20 discrete
capillary segments were examined using each of the above anti-
bodies. Mean scores of positive cells/glomerulus were calculated
for proliferation (PCNA + cells), and for the various leukocyte
populations. Semiquantitative scores of 0 to 4+ were used to
quantitate staining for the ECM components, a-actin, bFGF,
PDGF B-chain and PDGF 13-receptor and platelet infiltrates as
previously described [12, 29].
Double labeling
To determine the identity of proliferating (PCNA positive)
cells, a double immunogold staining method [12, 19] was utilized
in which tissue was stained first for PCNA and then stained with
either the OX-7 antibody to mesangial cells or the ED-I antibody
to macrophages and monocytes. PCNA positive cells were then
classified as either mesangial, macrophage, or non-classifiable as
previously described [12, 19].
Preparation of glomendar mRNA/Northem analysis
Glomeruli were isolated by differential sieving as described
previously [18]. All preparations studied had less than 10%
tubular contamination. Messenger RNA was isolated according to
the method of Chomczynski and Sacchi [30], modified using
RNAsoI B® (Tel-Test, Inc. Laboratories, Friendswood, TX, USA)
following the manufacturer's directions, with an additional over-
night precipitation in 3 M lithium chloride for further purification
[311. RNA was analyzed for content using standard 260/280 OD
spectrophotometric readings and corroborated on a 1% agarose
minigel. Northern analysis was performed with purified RNA
using 15 WIane, electrophoresed through a 1% agarose/1.1%
formaldehyde gel with ix MOPs buffer, and transferred to a nylon
filter (Hybond N, Amersham, Arlington Heights, IL, USA) as
described previously [321. The following cDNA probes were used
for analysis:
PDGF B-chain. The 3.4 kb rat PDGF B-chain transcript was
detected using a 3 kb EcoR I fragment of rat PDGF B-chain
cDNA clone p3-4a (gift of C.M. Giachelli, Seattle, WA, USA)
[321.
TGF-/31. A 985 bp Hind III/Xba I fragment of rat TGF-131
cDNA plasmid was used to detect the 2.4 kb rat TGF-f31
transcript (gift of Dr. Anita Roberts, NIH, Bethesda, MD, USA)
[33].
bFGF. A 539-bp Xho I/Nco I fragment of rat ovarian bFGF
cDNA from plasmid RObFGF-477 was used to detect the 6.8-kb
rat bFGF transcript [34].
Type IVcollagen, The 6.2 and 6.8 kb type IV collagen transcripts
were detected using a 1.8 kb EcoR I/Hind III cDNA fragment of
mouse al (IV) collagen (gift of M. Kurkinen) [35].
Laminin B2 chain. The 8 kb transcript was detected using a 1.7
kb EcoR I/Xba I fragment of mouse laminin B2 cDNA (gift of Y.
Yamada) [36].
28S. A bovine 280 bp cDNA probe was used to detect 28S
ribosomal RNA (gift of Dr. Luisa Iruela-Arispe and Dr. Helene
Sage).
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Variables measured
Time in weeks
2 4
Serum glucose mg/dl
DM 430 56 443 174
DM-INS 137 108 145 167
Control 146 12 147 22
Weight g
DM 237.0 9.6 279.1 24.8
DM-IN 246.7 14.3 300.4 29.2
Control 289.6 24.6a 370.9 34.la
Serum BUN mgldl
DM 30.2 5.0 27.8 4.96
DM-IN 25.0 5.7 30.0 5.4
Control 22.8 4.5 23.5 3.3
Serum creatinine mgldl
DM 0,32 0.04 0.30 0.13
DM-IN 0.37 0.05 0.35 0.19
Control 0.33 0.10 0.35 0.14
Urine protein mg/24 hr
DM 4.6 1.3 12.1 2.2
Control 2.9 •53 10.6 2.1
Urine volume ml
DM 23.1 6.5 23.7 2.3
Control 11.7 2.6a 12.9 2.8a
Results
All probes were labeled with [a-32P]-deoxycytidine 5-triphos-
phate (3000 Cilmmol, New England Nuclear, Boston, MA, USA)
by random primer extension. Filters were prehybridized and
hybridized as described previously [31]. Autoradiograms were
read by laser scanning using the Biosoft scan analysis program
(Burcham, Biosoft, Ferguson, MO, USA). All Northern analyses
were repeated with RNA preparations obtained from different
sets of animals. Some filters were rehybridized with additional
probes up to a maximal of four.
Platelet depletion studies
Platelet depletion was performed in seven rats with polyclonal
goat anti-platelet IgG as described elsewhere [18]. Control rats
(N = 6) received normal goat IgG. Streptozotocin was adminis-
tered eight hours after the anti-platelet antibody or normal goat
IgG serum injections. Platelet counts in platelet depleted animals
were less than 10,000 per mm3 at the time of streptozotocin
injection, and were maintained at this level until sacrifice at three
days.
Miscellaneous measurements
Urine protein was measured by the sulfosalicylic acid method
[37], using a whole serum standard (Lab Trol, Dade Diagnostics,
Aquado, Puerto Rico).
Statistical analysis
Data on macrophages, PCNA, PDGF, and platelets were tested
for statistically significant group differences using the nonpara-
metric Wilcoxon rank-sum test [38]. Data on other variables
studied are expressed as means and standard deviations and
analyzed for group differences using the two-sample Student's
I-test.
Metabolic characteristics of streptozotocin diabetes
Hyperglycemia exceeding 300 mg/dl was induced in the STZ
treated rats within 24 hours of STZ administration and remained
elevated throughout the 30 day study. The serum glucose in
diabetic animals was significantly different from insulin treated
animals at all time points from day three, except day six where
insulin treated animals had elevated serum glucose (243 128
mgldl compared to 352 140 in diabetes). Diabetic rats gained
less weight than controls (Table 1). Insulin treated diabetic
animals also gained less weight than controls (Table 1) but slightly
more than diabetic animals.
Diabetic animals did not have more proteinuria than controls
over the time course of the study except at two weeks, but were
significantly more polyuric than controls at two and four weeks
(Table 1).
Glomerular cellularity
Total glomerular cellularity was assessed by counting the total
number of nuclei per glomerulus in PAS stained sections and
subtracting the number of infiltrating cells (assessed by ED-i
staining for macrophages which were the primaly infiltrating
leukocyte population). There was no significant increase in total
nuclei in glomeruli from diabetic rats compared to control ani-
mals. However, cellularity was significantly higher in diabetic rats
compared to insulin treated diabetic animals at day six and 14
(data not shown).
PCNA staining was increased in diabetic rats at day three and
was normal in control and insulin-treated diabetic animals (Fig.
1). Increased proliferation continued in diabetic rats through day
30 and was significantly different from control animals and
insulin-treated diabetic animals except at day 30. Double immu-
nostaining (Table 2) confirmed that the majority (that is, 61 to
Table 1. Variables measured during the first thirty days of STZ-
diabetes
(
a,
E
5 .2
0
—0
+0
z0
a-
5
4
3
2
1
0
Abbreviations are: DM, diabetic animals; DM-IN, insulin-treated dia-
betic animals; BUN, blood urea nitrogen. Values are mean so.
ap < 0.05 versus diabetic animals.
0 5 10 15 20 25 30
Day
Fig. 1. Graph of proliferating cells determined by PCNA stain in diabetic
animals (— —), diabetic animals treated with insulin (— — —), and normal
control (—) animals during the first 30 days after STZ induction of
diabetes. Values are mean savi. * P < 0.05 vs. control; P < 0.05 vs.
insulin.
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Day PCNAJTHY-1 PCNAJED-1 Unclassified
3 69.16 1.26
6 61.08 2.41
14 61.95 4.79
8.92 3.69 21.7 9.91
8.96 2.84 30.4 7.31
5.05 2.06 33.0 10.55
To establish the nature of proliferating (PCNA-positive) cells in dia-
betic animals, double labeling was done with ED-i (monocyte/macro-
phages) and Thy 1 (mesangial cells) antibodies. Most PCNA-positive cells
(60 to 70%) were mesangial. PCNA-positive cells that were negative for
ED1 and Thy 1 were designated as unclassified.
a p < 0.05 diabetic animals vs. controls
'P < 0.05 diabetic animals vs. insulin treated diabetic animals
70%) of PCNA positive cells were mesangial cells at days three,
six, and 14, with 7 to 13% of the proliferating cells representing
macrophages and the rest unclassifiable.
Increased numbers of platelets were found to be present in
glomeruli of diabetic rats by day three compared to control
animals and insulin treated animals (Table 3). Platelets were also
identified by EM in glomerular capillaries of diabetic rats at day
three along with mononuclear leukocytes (Fig. 7). Platelet deple-
tion significantly decreased mesangial cell proliferation at day
three in diabetic rats compared to normal serum IgG treated
controls (1. 42 0.28 vs. 0.27 0.11 PCNA + cells/glom, respec-
tively, P < 0.003).
To determine if a change in mesangial cell phenotype occurs in
experimental diabetes, tissue was stained for cs-actin. De novo
mesangial expression of a-actin was documented in diabetic
animals at days one and three, and was significantly increased
compared to control and insulin treated animals (Fig. 2). No
difference in cw-actin expression was noted at later time points,
with all groups showing minimal to no a-actin expression.
A glomerular infiltrate of monocytes/macrophages was appar-
ent as early as day three, and was maximal at day 30 (Fig. 3). This
monocyte/macrophage infiltrate was not associated with neutro-
phils, or with B cells and T cells that express the common
leukocyte antigen. Insulin therapy reduced the number of infil-
trating cells to control levels except at one time point (day six)
when transient hyperglycemia occurred (Fig. 3).
Growth factor expression
A significant increase in bFGF immunostaining was noted in
the mesangium of diabetic rats at day three, and decreased to
baseline levels at days 14 and 30, when compared to controls and
insulin treated diabetic animals (Fig. 4). However, no increase in
bFGF mRNA could be documented in glomeruli at any time
point.
Immunostaining for PDGF B-chain showed a slight increase in
diabetic animals on day one and was persistently elevated com-
pared to controls and insulin treated diabetic animals over the 30
day time course (data not shown). PDGF B-chain mRNA was
minimally (10%) increased compared to control and insulin
treated diabetic animals at days one, six, 14, and 30 (Table 4).
PDGF a-subunit receptor staining was also slightly increased in
glomeruli of diabetic animals at day three compared to controls
but not thereafter (data not shown).
TGF-131 mRNA was also increased in glomeruli of diabetic
animals compared to controls or insulin treated diabetic animals
at day 14 and 30 (Fig. 5).
Extracellular matrix
Biopsies from diabetic animals were stained with PAS and silver
methenamine to assess changes in morphology, ECM expansion,
and progression to sclerosis. Staining with PAS showed mild
mesangiolysis as early as day three only in diabetic animals.
Mesangiolysis was not seen in controls or in insulin treated
animals. Silver and PAS staining confirmed some mesangial
matrix expansion by day 30 without sclerosis (data not shown). No
morphologic changes were seen in control or insulin treated
diabetic animals.
To determine if the cellular events described above preceded
changes in individual extracellular matrix components immuno-
histochemical staining for type I collagen, type IV collagen,
HSPG, and laminin was quantitated in mesangial matrix. The
abundance of glomerular mRNA for type IV collagen and laminin
was also assessed in diabetic, control, and insulin treated animals
at days one, three, six, 14 and 30. Immunohistochemical staining
for type I collagen was found not to be elevated over the first 30
days of streptozotocin induced diabetes. In contrast, type IV
collagen staining was found to be significantly increased in a
mesangial distribution in glomeruli by day 30 but not before (Fig.
6). However, this increase in immunohistochemical staining was
not associated with a significant increase in mRNA expression for
type IV (al) collagen (Table 4).
Laminin staining was also increased in diabetic animals when
compared to insulin-treated diabetic animals, but not control
animals at day 30 (data not shown). Messenger RNA for laminin
B2 was not significantly elevated in STZ diabetic rats at day 30
(Table 4).
A significant reduction in glomerular staining for HSPG was
found at days 14 and 30 in diabetic animals when compared to
control and insulin treated diabetic animals. The decreased
staining of HSPG was in both a mesangial and capillary loop
pattern (data not shown).
Discussion
Diabetic nephropathy (DN) exceeds hypertension as a cause of
end-stage renal disease in the United States [1]. However, the
cellular mechanisms of injury remain poorly understood. Multiple
mechanisms have been proposed for DN including abnormalities
in glomerular hemodynamics [3, 4, 39, 40], mesangial matrix
expansion [41] with glomerular hypertrophy [42, 43], aberration in
glomerular polyol/sorbitol pathways [5, 44], glycosylation of gb-
merular structures [7], increased sodium-lithium countertransport
[6, 45], abnormal growth factor expression leading to ECM
accumulation [8], and directly toxic effects of exogenous insulin
Table 2. Double immunostaining results Table 3. Immunostaining for platelets (0 to 4+) in glomeruli
Day Diabetes Control Insulin
1 0.79 0.15 0.65 0.26 —
3 1.0 0.05 0.68 0.16 0.66 025b
6 1.0 0.30 0.90 0.08 1.03 0.21
14 0.76 0.18 0.53 0.31 0.75 0.07
30 0.98 0.12 0.94 0.33 0.76 0.13
S.5. p
Fig. 2. Alpha actin expression at day three in diabetes (A), insulin-treated diabetic animals (B), and normal control animals (C). There is de novo expression
of alpha actin in a mesangial pattern in the diabetic animal (A), which is abolished by insulin therapy and not seen in controls. Alpha actin staining in
control and insulin-treated animals is in smooth muscle cells of the afferent arteriole (X400).
previously been recognized in vivo. Our study documents an
immediate change in mesangial cell phenotype as early as day one
after STZ administration manifested as de novo expression of
a-smooth muscle actin. This phenomenon has previously been
shown to be a feature of mesangial cell activation in several
experimental models of glomerular disease including the ATS
model of mesangial proliferative nephritis [31], Habu snake
venom glomerulonephritis (GN) [31], the remnant kidney model
of progressive glomerulosclerosis [12], and angiotensin TI-medi-
ated hypertension [47]. Moreover, we have recently recognized
mesangial cell a-actin expression as a feature of diabetes and
other glomerular diseases in humans [48]. The significance of this
phenotypic change is uncertain. In other models, it is accompa-
nied by de novo expression of type I collagen indicating that
mesangial cells acquire the characteristics of "myofibroblasts" in
response to several different forms of glomerular injury [10, 12].
Alpha-actin may also augment the mesangial contractile response
0 5 10 15 20 25 30 to the increased glomerular pressures and flows which occur early
in diabetes [49], thereby modulating local hemodynamics. The
Day prevention of a-actin expression by insulin administration sug-
gests that it occurs in response to the diabetic milieu rather than
as a consequence of STZ administration, a conclusion which
applies to the early hemodynamic changes in STZ diabetes as well
[50]. There was also a mild mesangiolysis seen in diabetic animals
that was not found in control or insulin treated animals and is
another recognized feature of diabetic nephropathy in humans
[51].
An additional finding in our study was a prominent glomerular
cell proliferation which was evident by day one, and peaked at day
three but persisted throughout the remaining 30 days of the study.
This confirms and extends the recent observation by Nakamura et
al of increased abundance of mRNA for PCNA in early strepto-
zotocin nephropathy in rats [52]. Double labeling studies demon-
strated that a majority of the proliferating cells were mesangial,
with a minor contribution from infiltrating macrophages. The
early proliferative response was totally abolished by insulin ther-
apy making any role for STZ in initiating mesangial cell prolifer-
ation less likely. Several recent studies from our laboratory have
described a similar wave of mesangial cell proliferation that
administration [46]. Our study describes two new mechanisms:
phenotypic activation and proliferation of the glomerular mesang-
ial cell, and a prominent glomerular monocyte/macrophage infil-
trate. Both of these events preceded the development of ECM
expansion and sclerosis.
It is generally accepted that the principal glomerular lesion in
diabetic nephropathy is mesangial matrix expansion which re-
duces the area for filtration and leads eventually to sclerosis and
renal failure [2]. While it seems probable that this process reflects
an abnormality in mesangial cell function leading to over produc-
tion or impaired degradation of new or novel matrix components,
no direct evidence for mesangial cell dysfunction in diabetes has
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Fig. 3. Time course of the glomerular monocytelmacrophage infiltrate in
diabetic animals (— —), insulin-treated diabetic animals (— — —) and control
animals (—). There was a persistent macrophage infiltrate in diabetic
animals that increased over 30 days and was decreased to control levels by
insulin therapy (except for one episode of transient hyperglycemia at day
six). Values are mean SCM. * P < 0.05 vs. control; t P < 0.05 vs. insulin.
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Fig. 4. Immunohistochemical staining for bFGF at day three in diabetic animals (A), insulin-treated diabetic animal (B), and normal controls (C). There
is an apparent increase in staining in the diabetic animal in a mesangial distribution which is abolished by insulin therapy (X400).
occurs in both immunologic [53] and non-immunologic [12] forms
of glomerular injury, and precedes increased extracellular matrix
deposition and later development of sclerosis. Mesangial cell
proliferation appears to be platelet-mediated, and may be initi-
ated by bFGF [17, 54], and maintained by PDGF [55] through an
autocrine mechanism involving increased mesangial cell produc-
tion of PDGF B-chain and PDGF 13-receptor [12, 32]. In diabetic
nephropathy we were able to demonstrate that glomerular cell
proliferation was reduced by platelet depletion and was accom-
panied by some increased staining for bFGF, as well as a modest
increase in glomerular PDGF B-chain staining and mRNA ex-
pression. However, the magnitude of these changes in bFGF and
PDGF was small, and further studies would be required to assess
their functional significance. Other stimuli for mesangial cell
proliferation in diabetes should be considered.
Of note was the finding that glomerular cell proliferation was
reduced in insulin treated diabetic animals compared to normal
controls. Insulin treated controls also gained significantly less
weight than normal animals suggesting that nutritional factors
may have affected cell proliferation. Protein restriction is known
to be reno-protective in diabetic nephropathy [56, 57] and to
inhibit expression of cytokines such as TGF-f3 [58]. However,
diabetic animals gained even less weight than insulin treated
controls which should have diminished rather than increased
cellular events. Thus the cellular events observed in diabetic
animals may have been even more prominent if not modified by
nutritional factors.
The finding of platelets early in STZ DN is significant since
platelets have been implicated in glomerular injury in human
diseases including DN [59]. Furthermore, use of platelet inhibi-
tors in DN decreases urinary protein excretion and thromboxane
B2 levels in humans [60, 61]. Thrombocytopenia induced with
anti-platelet serum significantly inhibited proliferation in this
model. Thus, platelets may be important in mediating the prolif-
erative response of mesangial cells in vivo, perhaps through
release of growth factors such as PDGF or bFGF [62].
In addition to the mesangial cell changes, our study also
established a significant increase in glomerular macrophages
which occurred as early as day three and increased progressively
through day 30. Like mesangial cell proliferation, the macrophage
Table 4. PDGF B chain, collagen IV and laminin B2 messenger RNA
expression in glomeruli from streptozotocin diabetic ratsa
Day Diabetes Control Insulin
PDGF BChaint 1
3
6
14
30
1.13
0.61
1.11
1.15
1.10
1.0
1.0
1.0
1.0
1.0
—
0.72
1.40C
0.92
0.83
Collagen Type IV" 1
3
6
14
30
1.07
0.68
1.08
1.04
0.81
1.0
1.0
1.0
1.0
1.0
—
0.76
1.31C
0.98
0.69
Laminin" 1
3
6
14
30
—
0.58
1.06
0.84
0.77
—
1.0
1.0
1.0
1.0
—
1.02
0.95
0.95
0.58
Expressed as relative densitometry units compared to control animals
assigned a value of 1.0bAll values are normalized to a 28S ribosomal RNA probe (see text)
The increase in PDGF-B chain and collagen IV mRNA noted on day
six in insulin-treated animals may reflect a one time only increase in blood
sugar in this group on day six (243 128 mgldl vs. 150 22 in controls and
352 139 in diabetic animals)
infiltrate was also decreased by insulin therapy. Again, this finding
is similar to what we have observed in other models of progressive
sclerosis involving the mesangium, including the anti-thymocyte
serum and remnant kidney models [18, 12]. Glomerular macro-
phages have also been prominently identified in a variety of other
progressive glomes-ular diseases in both animal models [63, 64],
and in humans [65], including diabetic nephropathy [66]. The
absence of a significant lymphocytic or neutrophilic infiltrate
suggests that the stimulus for macrophage accumulation may
derive from resident glomerular cells. Possible mesangial cell
derived chemotactic factors would include PDGF [9], TGF-/3 [67],
advanced glycosylation end-products (AGES) [68], carbohydrates
[69], monocyte chemotactic peptide (MCP-1/JE-protein) [70], or
macrophage inhibitory factor [71].
The consequences of this macrophage infiltrate in diabetic
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Fig. 5. Gene expression for TGF-f31 at days 14
and 30 in glomeruli from diabetic animals (DM),
normal controls (con) and insulin-treated diabetes
(INS-DM). Quantitation by densitometsy in
relative units compared to controls that are
assigned a value of 100 is shown below. TGF-p
mRNA is increased about 20% in diabetic
animals at both time points.
Fig. 6. Immunostaining for type iT/collagen at 30 days in a diabetic animal (A), insulin-treated diabetic animal (B), and normal control (C). There is a slight
increase in mesangial matrix staining for type IV collagen that preceded any evidence of matrix expansion or sclerosis (X400).
nephropathy were not defined. Macrophages may release a variety have been documented in other models of progressive sclerosis
of pro-inflammatory substances such as oxidants, proteases, tissue [73]. TGF-f3 is a potent stimulus for the production of extracel-
factor and various cytokines and growth factors [reviewed in 72]. lular matrix by glomerular and extra glomerular cells [74—76], and
Macrophages are also major effector cells in the mediation of collagen synthesis by glomeruli in STZ diabetes has been sug-
some types of acute immune glomerular injury [64]. However, a gested to be TGF-/3 dependent [76]. Moreover, neutralization of
more likely role for macrophages in the non-inflammatory early TGF-/3 in vivo using specific antibody or neutralizing protogly-
phase of diabetic nephropathy is as a source for TGF-f3. TGF-p cans has been reported to diminish glomerular matrix accumula-
mRNA was increased in glomeruli by day 14 and persisted for 30 tion and sclerosis in the ATS model of glomerulonephritis [77].
days, a finding similar to that recently reported by Border and The source of the increase in glomerular TGF-/3 mRNA has not
colleagues [8]. Similar increases in TGF-/3 mRNA and protein been established in glomerulonephritis or diabetic nephropathy,
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Fig. 7. Electron micrograph demonstrating circulating platelets (arrow) and mononuclear leukocytes (M) within glomerular capillaries in a diabetic animal
at day three (X4000).
and both mesangial cells and macrophages may be involved.
TGF-13 has been shown to be increased in vascular smooth muscle
cells in response to glucose [78], as well as in mesangial cells
where it is also a potent inhibitor of proliferation induced by high
glucose [79]. Thus, up-regulation of glomerular TGF-p precedes
deposition of ECM components such as collagen IV, and coin-
cides with continued glomerular macrophage influx and decreased
glomerular cell proliferation.
The cellular events described above preceded any detectable
increase in either staining or gene expression for ECM compo-
nents. However, some increased mesangial staining for type IV
collagen and laminin was detectable by 30 days, although no
increase in mRNA for these proteins was observed. Others
studying changes in ECM early in STZ diabetes have reported
conflicting results including a decrease in type IV (151) collagen
mRNA with normal laminin Bi mRNA levels [80] and a gener-
alized increase in mRNA for collagen I, IV and laminin Bi and B2
[81]. These differences probably relate to variations in experimen-
tal design and will require additional studies to reconcile.
To summarize and sequence our findings, we have documented
a very early (days 1 to 3) phase of mesangial cell proliferation
associated with de novo expression of cs-actin in STZ-induced
diabetic nephropathy. Mesangial cell proliferation is associated
with glomerular platelet localization and is blocked by platelet
depletion. These mesangial cell changes are associated with some
increase in glomerular mesangial content of bFGF and PDGF but
are probably mediated primarily by other metabolic and/or hor-
monal/hemodynamic factors. After mesangial cell proliferation is
in progress, there develops a prominent and persistent glomerular
macrophage infiltrate associated with an increase in glomerular
mRNA for TGF-f3. All of these cellular events precede any
detectable changes in glomerular gene expression or mesangial
accumulation of normal extracellular matrix components. It there-
fore seems likely that these cellular events are important in the
later development of diabetic glomeruloscierosis and may even
serve as early prognostic markers in this disease.
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